The Novo Nordisk Foundation does not plan to step in to prop up a global health sector reeling from a freeze on U.S.-funded foreign aid, and will continue to focus on its core non-communicable disease agenda, an official told Reuters.
The foundation, which is linked to the Danish drugmaker and is one of the world's largest charitable organizations, will prioritize funding work tackling conditions such as heart disease and diabetes, and risk factors like obesity, said Flemming Konradsen, scientific director of global health.
“Of course, more people are contacting us... We don’t have plans of stepping in, of filling gaps,” Konradsen said in an interview last week, when asked who could step in as governments rein in global health spending.
Since President Donald Trump took office on Jan. 20, the U.S. has frozen international aid, although some waivers for lifesaving assistance have been put in place. It will also quit the World Health Organization, news that sent shockwaves worldwide.
The foundation is the parent company of Novo Holdings, the controlling shareholder of Novo Nordisk, which makes the blockbuster obesity drug Wegovy and diabetes medication.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.